The green light for the operation of three AstraZeneca, Pfizer / BioNTech and Moderna vaccine production units in Europe was given by European Medicines Agency (EMA).
In particular, Coreper gave the green light for the operation of its vaccine production unit AstraZeneca in the Netherlands, which is at the heart of the dispute between London and the European Union, is facing problems in supplying vaccines against Covid-19.
It also approved the new Pfizer / BioNTech vaccine plant in Marburg, Germany, and the addition of new production lines Moderna vaccine in a Swiss unit.
The first AstraZeneca vaccines to be produced at the plant in the Netherlands are expected at the end of March, while the first batches of the Pfizer / BioNTech vaccine at the Marburg plant are expected to be delivered in early April.
The purpose of these changes is to increase the production capacity and supply of vaccines in the European Union market, as broadcast by Reuters and rebroadcast by the Athens News Agency.
The Halix plant in the Dutch city of Leiden, which produces doses of the AstraZeneca vaccine, is the subject of controversy between the European Union and the United Kingdom.
European Commission President Ursula von der Leyen warned yesterday that AstraZeneca, which has delivered to the European Union only 30 of the 120 million doses of the vaccine it has committed under its contract with the Commission, will deliver in the first quarter of the year, “Must first make up for the delays” and meet its contractual obligations before it can export vaccines outside Europe.
European Health Commissioner Stella Kyriakidou said that Coreper’s decision on the Halix unit means that within a few days additional quantities of vaccines will be delivered as part of the fulfillment of AstraZeneca’s contractual obligations to European citizens.
If it were not for the reduced deliveries of AstraZeneca, the percentage of vaccinations in the European Union would be doubled, added Stella Kyriakidou.
The approval of the operation of the Marburg plant will allow the acceleration of the production and deliveries of the vaccines expected under the supplementary contract with the BioNtech/Pfizer, also explained the European Commissioner.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
